Frequent expression of CD30 in extranodal NK/T ‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy
In conclusion, frequent expression of CD30 in ENKTL suggests anti‐CD30 antibody‐based therapy may be an effective treatment. (Source: Hematological Oncology)
Source: Hematological Oncology - October 20, 2017 Category: Hematology Authors: Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yuya Sasaki, Kyohei Yamada, Eriko Yanagida, Reiji Muto, Maiko Kiryu, Hirohito Sone, Masao Seto, Koichi Ohshima, Jun Takizawa Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Hematological Oncology, EarlyView. (Source: Hematological Oncology)
Source: Hematological Oncology - October 6, 2017 Category: Hematology Source Type: research
---
Hematological Oncology, Ahead of Print. (Source: Hematological Oncology)
Source: Hematological Oncology - October 6, 2017 Category: Hematology Source Type: research
Tocilizumab for severe cytokine ‐release syndrome after haploidentical donor transplantation in a patient with refractory Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma
Hematological Oncology,Volume 36, Issue 1, Page 324-327, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 3, 2017 Category: Hematology Source Type: research
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia
Hematological Oncology,Volume 36, Issue 1, Page 366-369, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 3, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 324-327, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 3, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 366-369, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 3, 2017 Category: Hematology Source Type: research
Tocilizumab for severe cytokine ‐release syndrome after haploidentical donor transplantation in a patient with refractory Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma
Abstract
It has been well documented that patients may develop cytokine‐release syndrome (CRS) following the administration of monoclonal antibodies, such as chimeric antigen receptor‐modified T cell. Cytokine‐release syndrome is a common complication in patients who have received haploidentical donor allogeneic haematopoietic cell transplantation (haplo‐HCT). Although severe CRS after haplo‐HCT is a potentially life‐threatening toxicity, a standard treatment has not been established. Cytokine blockade with tocilizumab, an anti‐IL‐6 receptor antibody, has been effective for the treatment of patients with CR...
Source: Hematological Oncology - October 3, 2017 Category: Hematology Authors: Hiroshi Ureshino, Toshihiko Ando, Haruna Kizuka, Kana Kusaba, Haruhiko Sano, Atsujiro Nishioka, Hidekazu Itamura, Takero Shindo, Yasushi Kubota, Kensuke Kojima, Shinya Kimura Tags: CASE REPORT Source Type: research
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome
Hematological Oncology, EarlyView. (Source: Hematological Oncology)
Source: Hematological Oncology - September 15, 2017 Category: Hematology Source Type: research
---
Hematological Oncology, Ahead of Print. (Source: Hematological Oncology)
Source: Hematological Oncology - September 15, 2017 Category: Hematology Source Type: research
Issue Information
No abstract is available for this article. (Source: Hematological Oncology)
Source: Hematological Oncology - September 14, 2017 Category: Hematology Tags: ISSUE INFORMATION Source Type: research
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia
This study included 276 patients, in 10 different MFC centers, of whom 268 had at least 1 MRD check point. The combination of a CD45, CD34, and CD33 backbone, with the addition of CD117, CD13, CD7, and CD15 in 2 five‐color tubes allowed to define each patient's multiparameter immunophenotypic characteristics at diagnosis, according to a Boolean combination of gates. The same individual diagnosis gating strategy was then applied at each MRD time point for each patient. MRD levels were stratified according to log by log thresholds, from 5 × 10−2 (the classical morphological threshold to define remission) down to <5...
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Francis Lacombe, Lydia Campos, Kaoutar Allou, Christine Arnoulet, Adrienne Delabarthe, Florent Dumezy, Jean Feuillard, Franck Genevi ève, Estelle Guérin, Julien Guy, Hélène Jouault, Pascale Lepelley, Marc Maynadié, Françoise Solly, Orianne Wagner Ba Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid
This study shows that sensitive MYD88 mutation analysis by ddPCR in CSF is highly reliable and can be applied even when DNA input is low. Therefore, ddPCR is of added value to current diagnostic parameters, especially when the available amount of DNA is limited. (Source: Hematological Oncology)
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Laura S. Hiemcke ‐Jiwa, Monique C. Minnema, Joyce H. Radersma‐van Loon, N. Mehdi Jiwa, Mirthe Boer, Roos J. Leguit, Roel A. Weger, Manon M.H. Huibers Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma
Abstract
Treatment of myeloma is a long‐term treatment mainly based on all‐oral combinations of drugs. Because oral drugs have a more complex pharmacokinetics compared with IV treatments, an appropriate knowledge of the factors that may alter their systemic exposure is of particular clinical relevance. Both drug‐drug interactions, food‐effect, and dose‐adaptation in renal and hepatic impairment may influence the systemic drug levels with a potential impact on drug efficacy or safety. Moreover, a better control of drug exposure may improve the side effect profiles of these treatments with a favourable impact on pa...
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Camille Morival, Sitty Oumari, Arthur Lenglet, Pascal Le Corre Tags: REVIEW Source Type: research
Role of BMI and age in predicting pathologic vertebral fractures in newly diagnosed multiple myeloma patients: A retrospective cohort study
This study recruited consecutive 394 patients with NDMM at Taipei Veterans General Hospital between January 1, 2005 and December 31, 2015. Risk factors for vertebral fractures in NDMM patients were collected and analyzed. The survival curves were demonstrated using Kaplan‐Meier estimate. In total, 301 (76.4%) NDMM patients were enrolled in the cohort. In the median follow‐up period of 18.0 months, the median survival duration in those with vertebral fractures ≥ 2 was shorter than those with vertebral fracture < 2 (59.3 vs 28.6 months; P = 0.017). In multivariate Poisson regression, BMI < 18.5 kg/m2 declared i...
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Yi ‐Lun Chen, Yao‐Chung Liu, Chia‐Hung Wu, Chiu‐Mei Yeh, Hsun‐I Chiu, Gin‐Yi Lee, Yu‐Ting Lee, Pei Hsu, Ting‐Wei Lin, Jyh‐Pyng Gau, Liang‐Tsai Hsiao, Tzeon‐Jye Chiou, Jin‐Hwang Liu, Chia‐Jen Liu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
